Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (35)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mattos, W.
Right arrow Articles by Barnes, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mattos, W.
Right arrow Articles by Barnes, P. J.
(Chest. 2002;122:1543-1552.)
© 2002 American College of Chest Physicians

Matrix Metalloproteinase-9 Expression in Asthma*

Effect of Asthma Severity, Allergen Challenge, and Inhaled Corticosteroids

Waldo Mattos, MD; Sam Lim, MBBS; Richard Russell, MB; Anon Jatakanon, MD; K. Fan Chung, MD, FCCP and Peter J. Barnes, DM

* From the Department of Thoracic Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK.

Correspondence to: Peter J. Barnes, DM, Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse St, London WS3 6LY, UK; e-mail: p.j.barnes{at}ic.ac.uk

Background: Asthma is associated with remodeling of the extracellular matrix (ECM) and increased airway obstruction, and the mechanisms of this process are unknown. Matrix metalloproteinases (MMPs) are a group of enzymes capable of degrading the ECM. They are released along with their inhibitors, tissue inhibitor of MMP (TIMP).

Study objectives: To determine whether severe, persistent asthma is associated with increased levels of MMP-9 in the airway compared with mild asthma, and to assess the effect of both allergen exposure and steroid treatment on MMP-9 and TIMP-1 levels.

Design: Prospective analysis of levels and activity of MMP-9 and TIMP-1 in BAL fluid (BALF) and induced sputum obtained from asthmatics of differing disease severity. In patients with mild asthma, MMP-9 and TIMP-1 levels were studied in induced sputum following allergen challenge and in BALF after inhaled steroid therapy.

Patients: Eighteen patients with mild asthma, 10 patients with severe asthma, and 10 nonsmoking, atopic subjects had their sputum studied. Fourteen of the patients with mild asthma underwent allergen challenge. BAL was collected from 16 patients with mild asthma before and after 4 weeks treatment with inhaled budesonide, 800 µg bid, or placebo.

Results: Patients with severe asthma had increased levels and activity of sputum MMP-9 in their sputum compared with patients with mild asthma and normal subjects. Allergen challenge increased the MMP-9/TIMP-1 ratio and MMP-9 activity. Inhaled budesonide had no effect on MMP-9 or TIMP-1 in patients with mild asthma.

Conclusions: MMP-9 may play a role in chronic airway inflammation and remodeling in asthma, as concentrations are increased in severe, persistent asthma and following allergen challenge. Inhaled steroids may not affect MMP-9 and TIMP in patients with mild asthma, and additional studies in patients with more severe asthma are needed.

Key Words: allergen challenge • asthma • corticosteroid • matrix metalloproteinase • matrix metalloproteinase-9 • tissue inhibitors of matrix metalloproteinase




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J. L. Simpson, R. J. Scott, M. J. Boyle, and P. G. Gibson
Differential Proteolytic Enzyme Activity in Eosinophilic and Neutrophilic Asthma
Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 559 - 565.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
F Lose, P J Thompson, D Duffy, G A Stewart, and M-A Kedda
A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women
Thorax, August 1, 2005; 60(8): 623 - 628.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
F. W.S. Ko, C. Diba, M. Roth, K. McKay, P. R.A. Johnson, C. Salome, and G. G. King
A Comparison of Airway and Serum Matrix Metalloproteinase-9 Activity Among Normal Subjects, Asthmatic Patients, and Patients With Asthmatic Mucus Hypersecretion
Chest, June 1, 2005; 127(6): 1919 - 1927.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. Linden, M. Laan, and G. P. Anderson
Neutrophils, interleukin-17A and lung disease
Eur. Respir. J., January 1, 2005; 25(1): 159 - 172.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. Wingett and C. P. Nielson
Divergence in NK cell and cyclic AMP regulation of T cell CD40L expression in asthmatic subjects
J. Leukoc. Biol., October 1, 2003; 74(4): 531 - 541.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
Y Oshita, T Koga, T Kamimura, K Matsuo, T Rikimaru, and H Aizawa
Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma
Thorax, September 1, 2003; 58(9): 757 - 760.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

MMP inhibitors in Severe Asthma and COPD
Dr S K Agarwal
Chest Online, 19 Dec 2002 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Chest Physicians.